Skip to main content

Table 3 Adjusted odds ratios for metabolic syndrome, colon cancer, and rectal cancer risks according to VEGF 3′-UTR variants

From: Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans

    MetS risk CC risk RC risk
Genotype/Haplotype Model Wild type AOR (95% CI)* p AOR (95% CI)** p AOR (95% CI)** p
VEGF 1451C > T Additive CC 0.80 (0.61 - 1.05) 0.105 1.05 (0.79 - 1.39) 0.742 1.40 (1.03 - 1.91) 0.031
  Dominant CC 0.85 (0.62 - 1.16) 0.295 1.04 (0.74 - 1.46) 0.813 1.58 (1.09 - 2.28) 0.015
  Recessive CC 0.36 (0.14 - 0.96) 0.041 1.16 (0.53 - 2.57) 0.709 1.12 (0.45 - 2.80) 0.804
VEGF 1612G > A Additive GG 1.02 (0.76 - 1.36) 0.920 0.82 (0.59 - 1.12) 0.216 0.83 (0.58 - 1.18) 0.304
  Dominant GG 1.11 (0.80 - 1.54) 0.521 0.81 (0.57 - 1.15) 0.239 0.74 (0.50 - 1.11) 0.149
  Recessive GG 0.38 (0.11 - 1.33) 0.130 0.68 (0.21 - 2.21) 0.521 1.48 (0.52 - 4.19) 0.458
VEGF 1725G > A Additive GG 1.61 (1.06 - 2.46) 0.026 1.34 (0.83 - 2.16) 0.235 1.51 (0.90 - 2.55) 0.118
  Dominant GG 1.61 (1.06 - 2.46) 0.026 1.34 (0.83 - 2.16) 0.235 1.51 (0.90 - 2.55) 0.118
  Recessive GG - - - - - -
VEGF 1451C/1612G/1725G   Others 1.14 (0.92 - 1.43) 0.232 1.04 (0.82 - 1.31) 0.762 0.87 (0.67 - 1.12) 0.279
VEGF 1451T/1612G/1725G   Others 0.80 (0.61 - 1.05) 0.101 1.05 (0.79 - 1.41) 0.735 1.40 (1.03 - 1.92) 0.030
VEGF 1451C/1612A/1725G   Others 0.73 (0.50 - 1.07) 0.111 0.69 (0.47 - 1.02) 0.066 0.56 (0.34 - 0.90) 0.017
VEGF 1451C/1612A/1725A   Others 1.54 (1.02 - 2.34) 0.041 1.12 (0.69 - 1.80) 0.652 1.42 (0.86 - 2.36) 0.170
  1. Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF). *AORs and p values were adjusted by age and gender. **AORs and p values were adjusted by age, gender, and MetS risk factors.
\